中国实用医刊
中國實用醫刊
중국실용의간
CENTRAL PLAINS MEDICAL JOURNAL
2014年
14期
50-51,87
,共3页
原发性肾病综合征%糖皮质激素%儿童%青少年%生长激素%矮小
原髮性腎病綜閤徵%糖皮質激素%兒童%青少年%生長激素%矮小
원발성신병종합정%당피질격소%인동%청소년%생장격소%왜소
Primary nephrotic syndrome%Glucocorticoid%Children%Adolescents%Human growth hormone%Short stature
目的：研究长期应用糖皮质激素治疗原发性肾病综合征对患儿生长激素（hGH）分泌的影响。方法选择商丘市第一人民医院2008年3月至2012年2月诊治的20例原发性肾病综合征患儿，平均年龄为（10.3±1.1）岁，均使用0.5~2.0 mg/（kg·d）的泼尼松治疗6~18个月。随访评价患儿的生长发育情况，每例患儿均行2种 hGH 兴奋试验并分析结果。结果20例患儿在服用泼尼松治疗期间生长速度显著减慢，平均（1.3±0.3）cm/年，泼尼松治疗前为（3.6±1.3）cm/年，差异有统计学意义（P <0.05）。17例患者行2项 hGH 兴奋试验的 hGH 峰值均<10 ng/ ml。与泼尼松治疗6~12个月的患儿相比，治疗>12个月的患儿 hGH 分泌异常发生率明显增高（P <0.05）。泼尼松用量为0.5~1.0 mg/（kg·d）与用量为1.0~2.0 mg/（kg·d）的患儿 hGH 分泌异常的发生率相比，差异无统计学意义（P >0.05）。结论长期服用泼尼松治疗原发性肾病综合征，能抑制患儿的 hGH分泌，从而影响患儿的生长发育。
目的：研究長期應用糖皮質激素治療原髮性腎病綜閤徵對患兒生長激素（hGH）分泌的影響。方法選擇商丘市第一人民醫院2008年3月至2012年2月診治的20例原髮性腎病綜閤徵患兒，平均年齡為（10.3±1.1）歲，均使用0.5~2.0 mg/（kg·d）的潑尼鬆治療6~18箇月。隨訪評價患兒的生長髮育情況，每例患兒均行2種 hGH 興奮試驗併分析結果。結果20例患兒在服用潑尼鬆治療期間生長速度顯著減慢，平均（1.3±0.3）cm/年，潑尼鬆治療前為（3.6±1.3）cm/年，差異有統計學意義（P <0.05）。17例患者行2項 hGH 興奮試驗的 hGH 峰值均<10 ng/ ml。與潑尼鬆治療6~12箇月的患兒相比，治療>12箇月的患兒 hGH 分泌異常髮生率明顯增高（P <0.05）。潑尼鬆用量為0.5~1.0 mg/（kg·d）與用量為1.0~2.0 mg/（kg·d）的患兒 hGH 分泌異常的髮生率相比，差異無統計學意義（P >0.05）。結論長期服用潑尼鬆治療原髮性腎病綜閤徵，能抑製患兒的 hGH分泌，從而影響患兒的生長髮育。
목적：연구장기응용당피질격소치료원발성신병종합정대환인생장격소（hGH）분비적영향。방법선택상구시제일인민의원2008년3월지2012년2월진치적20례원발성신병종합정환인，평균년령위（10.3±1.1）세，균사용0.5~2.0 mg/（kg·d）적발니송치료6~18개월。수방평개환인적생장발육정황，매례환인균행2충 hGH 흥강시험병분석결과。결과20례환인재복용발니송치료기간생장속도현저감만，평균（1.3±0.3）cm/년，발니송치료전위（3.6±1.3）cm/년，차이유통계학의의（P <0.05）。17례환자행2항 hGH 흥강시험적 hGH 봉치균<10 ng/ ml。여발니송치료6~12개월적환인상비，치료>12개월적환인 hGH 분비이상발생솔명현증고（P <0.05）。발니송용량위0.5~1.0 mg/（kg·d）여용량위1.0~2.0 mg/（kg·d）적환인 hGH 분비이상적발생솔상비，차이무통계학의의（P >0.05）。결론장기복용발니송치료원발성신병종합정，능억제환인적 hGH분비，종이영향환인적생장발육。
Objective To investigate the effect of long-term glucocorticoid treatment on human growth hormone(hGH)secretion in children and adolescents with primary nephrotic syndrome. Methods From March 2008 to February 2012,20 children and adolescents with primary nephrotic syndrome were chose,with(10. 3 ± 1. 1)years old. They were all given prednisolonc with a dose of 0. 5 -2. 0 mg /(kg·d)for 6 - 18 months. Two different hGH stimulating tests were done and their growth and development was evaluated at regular intervals. Results The growth speed of the 20 children decreased significantly during prednisolone treatment,which was(1. 3 ± 0. 3)cm/ year,and that before predniso-lone treatment was(3. 6 ± 1. 3)cm/ year,there was significant difference(P < 0. 05). The plasma levels of hGH were under 10 ng / ml in 17 patients underwent two hGH exciting experiments. The incidence of hGH secretion abnormality was significantly higher in children with prednisolone treatment course > 12 months than that in children with prednisolone treatment course of 6 - 12 months(P < 0. 05). There was no significant difference in the incidence of hGH secretion abnormality between children with prednisolone dose of 0. 5 - 1. 0 mg /( kg·d)and children with prednisolone dose of 1. 0 - 2. 0mg /( kg·d)( P >0. 05). Conclusions The long-term glucocorticoid treatment for primary nephrotic syndrome can de-crease the hGH secretion,and thus leads to short stature and agenesis.
